<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Complementary and alternative treatments for anxiety symptoms and disorders: Herbs and medications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Complementary and alternative treatments for anxiety symptoms and disorders: Herbs and medications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Complementary and alternative treatments for anxiety symptoms and disorders: Herbs and medications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexander Bystritsky, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2255973"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anxiety disorders are among the most common mental health problems in the United States. Many patients with anxiety disorders find conventional (Western) mental health care treatments to be insufficiently helpful and turn to complementary and alternative medicine (CAM) as an adjunct or substitute.</p><p>Epidemiologic studies suggest that 30 to 43 percent of patients treated in primary care for anxiety use CAM remedies as at least part of their treatment [<a href="#rid1">1-3</a>]. Clinicians would be well prepared to know about efficacy and safety of CAM treatments available for anxiety disorders.</p><p>Herbal remedies and dietary supplements used as complementary and alternative medical treatments for anxiety symptoms and disorders are described here. Complementary and alternative treatments involving physical, cognitive, or spiritual activities for anxiety symptoms and disorders are described separately. Herbal medicine and dietary supplements in general medical care are also described separately. (See  <a class="medical medical_review" href="/d/html/103407.html" rel="external">"Complementary and alternative treatments for anxiety symptoms and disorders: Physical, cognitive, and spiritual interventions"</a> and  <a class="medical medical_review" href="/d/html/1392.html" rel="external">"Overview of herbal medicine and dietary supplements"</a>.)</p><p class="headingAnchor" id="H109704336"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Sixty-two percent of adults in the United States utilize some form of complementary and alternative medical treatments [<a href="#rid3">3</a>]; the most commonly used were mind-body therapies. Individuals diagnosed with a psychiatric illness are more prone to using these therapies, especially patients with elevated anxiety or anxiety disorders [<a href="#rid4">4,5</a>], in part because many who are treated psychiatrically respond only partially to treatment and have residual symptoms and impairment [<a href="#rid6">6</a>].</p><p>Among the challenges encountered with evaluating the efficacy and clinical use of herbal remedies and dietary supplements for anxiety symptoms and disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Rigorous clinical trials of pharmacotherapy for anxiety disorders have shown rates of placebo response as high as 50 percent [<a href="#rid7">7</a>]. Determinations of efficacy thus require well-designed trials in sufficiently sized samples. Instead, most trials have had small samples and other methodological limitations. Large-scale safety studies have been scarce and inconclusive. Interactions among different herbal remedies have received insufficient study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consumers in the United States spend billions of dollars annually on herbal remedies and dietary supplements. This has fueled aggressive marketing campaigns, with claims of safety and efficacy for anxiety. Although often sold in pharmacies, these products are not subject to US Food and Drug Administration (FDA) regulations in the United States. Preparations can vary widely in dose and in composition of extracts and alkaloids, depending on the source.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many herbal remedies are largely used as a part of complex treatment strategies within Chinese, Tibetan, or Ayurveda medical systems. Evaluating their effects as a single remedy using Western testing methods and outcome measures, while useful, is incomplete. In addition, language barriers and selective databases limit access to clinical research from other countries.</p><p></p><p>Clinicians have an important role in educating patients about herbal remedies and dietary supplements. They should warn patients that the safety and efficacy of these products for anxiety symptoms and disorders is still unproven, and help them weigh the risks and benefits of using them adjunctively. Patients should be discouraged from abandoning evidence-based psychotherapies and medications for anxiety disorders. A patient’s medical history should include what remedies and supplements they are taking, particularly those known to interact with other drugs or cause adverse effects.</p><p>In addition to describing complementary and alternative treatments for anxiety disorders, this topic includes obsessive-compulsive disorder (OCD), which was placed into a separate category of disorders in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). (See  <a class="medical medical_review" href="/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis", section on 'Assessment and diagnosis'</a>.)</p><p class="headingAnchor" id="H2255826"><span class="h1">HERBAL REMEDIES</span><span class="headingEndMark"> — </span>None of the herbal remedies described here has been shown in clinical trials to be clearly effective or ineffective for anxiety symptoms or disorders. Potentially serious adverse effects are described below. Safety during pregnancy is not established. Mechanisms for anxiety reduction suggest involvement of gamma aminobutyric acid (GABA) [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2255833"><span class="h2">Kava-kava</span><span class="headingEndMark"> — </span>Kava-kava or kava (<em>Piper methysticum</em>) has been used for medicinal, religious, and social purposes in various cultures in the South Pacific Rim. The remedy traditionally comes from the root, which is combined with water to make an emulsion. Western phytopharmaceutical producers may use other parts of the plant to make pills, eg, stems, leaves, peelings, and bark with an ethanol or acetone solvent.</p><p>The principal active ingredients of kava remedies are called kavalactones; 15 have been identified, all with psychoactive properties. The mechanism of action is not known; research suggests a modulation of GABA activity and inhibition of noradrenaline and dopamine reuptake [<a href="#rid9">9,10</a>].</p><p>Two meta-analyses of multiple randomized trials [<a href="#rid11">11-27</a>] found kava to reduce anxiety in patients with elevated symptom levels [<a href="#rid28">28,29</a>]. As an example, a meta-analysis of seven randomized trials of 380 participants with elevated anxiety symptoms found that kava extract reduced anxiety as measured by the Hamilton Anxiety (HAM-A) scale compared with participants receiving placebo (weighted mean difference 3.9, 95% CI 0.1-7.7) [<a href="#rid29">29</a>]. Most of the trials had methodological flaws, small sample sizes, and conflicts of interest.</p><p>Side effects of kava include headaches, sedation, and sleepiness.</p><p>Numerous reports of severe hepatotoxicity and liver failure have been described in Europe and the United States, occurring within a few weeks to up to two years (average 4.5 months) following ingestion [<a href="#rid30">30-36</a>]. The US Food and Drug Administration (FDA) advised that kava should be used with caution in patients with preexisting liver disease or at risk for liver disease [<a href="#rid37">37</a>]. Hepatotoxicity and kava are discussed in further detail separately. (See  <a class="medical medical_review" href="/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements", section on 'Kava-kava'</a>.)</p><p class="headingAnchor" id="H2255840"><span class="h2">Valerian</span><span class="headingEndMark"> — </span>Valerian root (<em>Valeriana officinalis</em>), first described by Hippocrates, has sedative and anxiolytic effects. Various compounds have been detected in valerian, including alkaloids, flavonoids, and GABA. Its mechanism of action is not known, but appears to have a relationship with valerian root affinity for the GABA receptor.</p><p>Valerian was not found to reduce anxiety compared with placebo in a single small trial. A clinical trial randomly assigned 36 patients with generalized anxiety disorder (GAD) to daily valerian, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, or placebo [<a href="#rid38">38</a>]. After four weeks, there were no significant differences on the HAM-A scale or in side effects between patients treated with valerian compared with placebo.</p><p>Few adverse events have been reported as a result of valerian. Consistent with its sedative properties, valerian can cause drowsiness or dizziness. The risk of respiratory depression should be considered if valerian is proposed for use in the context of multiple sedating drugs and/or significant alcohol consumption. Valerian can cause abdominal pain in large doses.</p><p class="headingAnchor" id="H2255847"><span class="h2">Passion flower</span><span class="headingEndMark"> — </span>Passion flower (<em>Passiflora incarnata</em>) is traditionally used as a calming herb in the Americas and Europe. Its extract is also used as flavoring in foods and beverages.</p><p>The anxiolytic effects of passion flower are milder than for kava or valerian; it is thus most common to find passion flower marketed in combination with other herbs. A combined product, Euphytose (EUP), contains passion flower, crataegus, ballota, valerian, cola, and <em>Paullinia</em>.</p><p>Two small trials of passion flower showed mixed results. As an example, a trial of 90 patients with presurgical anxiety found that patients treated with passion flower experienced less anxiety compared with patients treated with placebo [<a href="#rid39">39</a>]. EUP has not been tested in a randomized trial.</p><p>Side effects of passion flower are rare but could include drowsiness, sedation, nausea, vomiting, and dizziness.</p><p class="headingAnchor" id="H2255854"><span class="h2">Chamomile</span><span class="headingEndMark"> — </span>Chamomile (<em>Matricaria recutita</em>) has been used for thousands of years for anxiety as well as other conditions. Research in animals has found evidence of anti-inflammatory [<a href="#rid40">40</a>], antihyperglycemic [<a href="#rid41">41</a>], antigenotoxic [<a href="#rid42">42</a>], and anticancer [<a href="#rid43">43-45</a>] properties in chamomile; these findings have not been reproduced in human studies.</p><p>Clinical trials of chamomile extract for GAD have shown mixed results:</p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial compared chamomile extract with placebo in 57 patients with mild to moderate GAD, finding the treatment to reduce anxiety on the HAM-A scale compared with the placebo group [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial of 93 patients who responded to chamomile for GAD were randomly assigned to six months of continued chamomile or placebo [<a href="#rid47">47</a>]. At the end of the trial, no difference was seen between groups in the proportion that relapsed.</p><p></p><p>Chamomile has been reported to increase anticoagulant properties of other medications and should thus be used with caution in patients whose anticoagulation status requires international normalized ratio (INR)<strong> </strong>monitoring. Adverse reactions ranging from simple dermatitis to severe anaphylaxis have also been described [<a href="#rid48">48,49</a>], but large-scale safety data have not been accumulated.</p><p class="headingAnchor" id="H3914792501"><span class="h2">Saffron</span><span class="headingEndMark"> — </span>Saffron is the dried stigmata of <em>Crocus sativus L</em>. In traditional medicine, it is used for the treatment of several conditions including cramps, depression, and asthma. It also has been studied in use for depression.</p><p>Two clinical trials, both with methodologic limitations, showed greater reductions in anxiety and depression with saffron compared with placebo:</p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial randomly assigned sixty adult patients with generalized anxiety and depression to receive a 50 mg saffron capsule or a placebo capsule twice daily for 12 weeks [<a href="#rid50">50</a>]. At the end of the trial, patients in the saffron group experienced greater reductions in anxiety and depression compared with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial of 40 patients with major depression treated with either <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> or <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> were randomly assigned to receive crocin, the main ingredient of saffron, or placebo as an adjunct treatment [<a href="#rid51">51</a>]. At the end of the trial, patients receiving crocin showed greater reductions in anxiety and depression compared with placebo.</p><p></p><p class="headingAnchor" id="H2255861"><span class="h2">St. John’s wort</span><span class="headingEndMark"> — </span>St. John’s wort (<em>Hypericum perforatum</em>) is widely prescribed as an antidepressant and anxiolytic remedy, especially in Europe. The mechanism of action is not known. Weak monoamine oxidase inhibiting (MAOI) properties have been suggested [<a href="#rid52">52</a>].</p><p>There is no evidence of efficacy for St. John’s wort in anxiety disorders. Small trials suggest the remedy may reduce anxiety associated with other mental disorders (below). It has been tested more extensively for depression. (See  <a class="medical medical_review" href="/d/html/1391.html" rel="external">"Clinical use of St. John's wort"</a> and  <a class="medical medical_review" href="/d/html/90155.html" rel="external">"Unipolar depression in adults: Investigational and nonstandard treatment", section on 'St. John's wort'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obsessive-compulsive disorder/social anxiety disorder</strong> – Clinical trials of St. John's wort for obsessive-compulsive disorder (OCD) and social anxiety disorder reported negative results [<a href="#rid53">53,54</a>]. As an example, a clinical trial randomly assigned 60 patients with OCD to receive St John's wort or placebo. After 12 weeks, no difference in OCD symptom change was seen between groups, nor in the percent of patients responding to treatment (17.9 versus 16.7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anxiety </strong>– There are no trials of St. John’s wort for anxiety as a primary outcome of treatment. Reduction in associated anxiety has been reported as a secondary outcome in two clinical trials of St. John’s wort, one in patients with major depression, the other in patients with somatization disorder [<a href="#rid55">55,56</a>].</p><p></p><p>The combination of St. John’s wort and selective serotonin reuptake inhibitor (SSRI) antidepressants can cause serotonergic syndrome and should be avoided [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H2255868"><span class="h2">Other herbals</span><span class="headingEndMark"> — </span>Other less well-known herbs received some study for anxiety, but generally with significant methodologic limitations or negative results:</p><p class="bulletIndent1"><span class="glyph">●</span>Keenmind (<em>Bacopa monnieri</em>) [<a href="#rid58">58</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Lemongrass (<em>Cymbopogon citratus</em>) [<a href="#rid59">59</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Rhodax (<em>Rhodiola rosea</em>) [<a href="#rid60">60</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Skullcap (<em>Scutellaria lateriflora)</em> [<a href="#rid61">61</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Silexan (lavender oil) [<a href="#rid62">62</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><em>Melissa officinalis</em> leaf extract [<a href="#rid63">63,64</a>]</p><p></p><p>Borage (<em>Echium amoenum</em>) and milk thistle (<em>Silybum marianum</em>) have shown promising results for OCD in small clinical trials [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H109704139"><span class="h1">DIETARY SUPPLEMENTS</span></p><p class="headingAnchor" id="H3104362305"><span class="h2">Essential nutrients and their source</span><span class="headingEndMark"> — </span>Nutrients, including vitamins, minerals, omega-3 (n-3) polyunsaturated fatty acids (PUFAs), and amino acids, are obtained through dietary intake of fruits, vegetables, nuts, and seafood. Many people are deficient in essential nutrients due to Western diets high in processed foods [<a href="#rid67">67</a>]. Nutrients are classified as "essential" when they are needed for the body's biologic processes but are not produced in adequate amounts by the body and must be obtained through dietary consumption [<a href="#rid67">67</a>]. Deficient levels of essential nutrients can result in the dysfunction of biological systems and can only be recovered by replenishment of required concentrations [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H379367554"><span class="h2">Specific essential nutrients</span></p><p class="headingAnchor" id="H109704154"><span class="h3">Zinc</span><span class="headingEndMark"> — </span>Zinc is an essential chemical element and plays an important role in replication, transcription, and protein synthesis for DNA as well as in expression of genes, storage of hormones, and reparation of tissues in humans. Zinc has been found to influence N-methyl-D-aspartate (NMDA) and gamma aminobutyric acid (GABA), neurotransmitter systems believed to be involved in obsessive-compulsive disorder (OCD) and in anxiety disorders [<a href="#rid67">67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obsessive-compulsive disorder</strong> – Study results have led researchers to postulate a relationship between zinc deficiency and OCD:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study of blood levels of trace elements in 48 participants with OCD and 48 healthy controls found an inverse correlation between the severity of OCD symptoms and zinc levels [<a href="#rid68">68</a>]. Lower levels of iron and magnesium were seen in the OCD group, but these levels were not correlated with OCD symptom severity [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A small clinical trial found evidence of benefit of zinc supplementation of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> treatment for OCD. Twenty-three patients with OCD were randomly assigned to receive either fluoxetine (20 mg/day) and zinc (440 mg/day) or fluoxetine (20 mg/day) and placebo [<a href="#rid69">69</a>]. After eight weeks, patients in the supplemented group had lower scores on the Yale Brown Obsessive-Compulsive Scale (Y-BOCS) compared with those in the control group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panic disorder </strong>– A study of trace element concentrations in 54 subjects with panic disorder and 52 healthy persons suggests an association between low levels of zinc and panic disorder [<a href="#rid70">70</a>]. Blood levels of manganese, zinc, calcium, copper, and magnesium were measured in all subjects. Blood concentrations of participants with panic exhibited lower levels of zinc compared with controls; other trace element concentrations were not related to disorder status.</p><p></p><p class="headingAnchor" id="H109704176"><span class="h3">Magnesium</span><span class="headingEndMark"> — </span>Magnesium is obtained through dietary intake of food such as dark, leafy greens; nuts; seeds; avocado; soybeans; and bananas. It is an essential element required for biological homeostasis, glucose metabolism, as well as synthesis of proteins and is a cofactor for over 300 enzymes [<a href="#rid67">67</a>]. Case histories and preclinical studies have found evidence for associations between magnesium deficiency and anxiety and depressive behaviors, as well as improvements in these symptoms after supplementation [<a href="#rid67">67,71</a>].</p><p class="headingAnchor" id="H109704182"><span class="h3">Vitamin E</span><span class="headingEndMark"> — </span>Vitamin E (alpha-tocopherol) is an antioxidant that is believed to have a protective effect against free oxygen radicals and lipid peroxidation (a biomarker for stress-induced oxidative cellular damage). Vitamin E has been hypothesized to exert its anxiolytic effect through protective antioxidant effects and decreasing of cortisol levels.</p><p>Findings from clinical studies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of lipid peroxidation and elevated anxiety in 80 subjects with OCD, social anxiety disorder, panic disorder [<a href="#rid72">72</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased vitamin E plasma levels and elevated malondialdehyde levels in 37 subjects with generalized anxiety disorder (GAD) compared with 20 healthy controls [<a href="#rid72">72</a>]</p><p></p><p class="headingAnchor" id="H109704197"><span class="h3">Antioxidant vitamins</span><span class="headingEndMark"> — </span>The antioxidant vitamins A, C, and E have been studied as a group for their effect on anxiety. A study found levels of the vitamins<strong> </strong>to be lower in 40 patients with GAD and 40 patients with major depression compared with 20 healthy control patients [<a href="#rid72">72</a>].</p><p>Participants with GAD in the previous study were randomly assigned to receive either <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a> or alprazolam plus vitamins A, C, and E daily [<a href="#rid72">72</a>]. After six weeks, participants who received vitamin supplementation had increased blood levels of the three vitamins and lower scores on the Hamilton Anxiety (HAM-A) scale compared with controls.</p><p class="headingAnchor" id="H109704210"><span class="h3">B vitamins</span><span class="headingEndMark"> — </span>B vitamins are essential for the creation of serotonin neurotransmitters, and vitamin B deficiency has been associated with anxiety and depressive symptoms [<a href="#rid73">73,74</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin B</strong><strong><sub>6</sub></strong><strong> and folate</strong> – A study of 907 female adolescent subjects found that folate and vitamin B<sub>6</sub> were negatively correlated with symptoms of depression and anxiety [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin B</strong><strong><sub>12</sub></strong><strong> </strong>–<strong> </strong>A study comparing 35 subjects with OCD with 22 healthy controls found a greater proportion with vitamin B<sub>12</sub> deficiency in subjects with OCD compared with controls [<a href="#rid76">76</a>]. Subjects with OCD had higher homocysteine levels, which positively correlated with Y-BOCS compulsion and Y-BOCS total scores.</p><p></p><p class="headingAnchor" id="H36732556"><span class="h3">Vitamin D</span><span class="headingEndMark"> — </span>Vitamin D, especially vitamin D<sub>3,</sub> plays an important role in brain plasticity, neuroimmunomodulation. It is derived from sunshine and fish with higher fat contents [<a href="#rid77">77,78</a>]. Research has suggested a possible relationship between vitamin D deficiency and vulnerability to depression and anxiety.</p><p>Clinical research findings on the relationship between vitamin D serum levels and anxiety severity have been mixed:</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 80 patients with chronic hemodialysis reported an association between anxiety severity scores and plasma levels of 25-hydroxy vitamin D [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a six-week clinical trial of the effect of vitamin D supplementation on affect and cognition in young adults, no difference was found in anxiety levels between vitamin D recipients and those given placebo [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial of 322 subjects who experienced an earthquake were randomly assigned to receive vitamin D<sub>3</sub> or placebo as a treatment for stress and anxiety. After 18 months of treatment, there was no difference between groups in anxiety or stress symptom change [<a href="#rid81">81</a>].</p><p></p><p class="headingAnchor" id="H109704230"><span class="h3">Glycine</span><span class="headingEndMark"> — </span>Glycine, an NMDA receptor agonist, has been shown to increase glutamatergic neurotransmission, which is known to be dysregulated in individuals with OCD [<a href="#rid82">82</a>]. Glycine has been studied as a potential adjunctive treatment for OCD. A clinical trial of 24 participants with OCD compared adjunctive daily treatment with glycine with placebo over 12 weeks. Participants receiving glycine exhibited a statistically nonsignificant trend toward lower Y-BOCS scores compared with the placebo group.</p><p class="headingAnchor" id="H109704237"><span class="h3">Inositol</span><span class="headingEndMark"> — </span>Inositol, a naturally occurring isomer of glucose derived from the human diet, is concentrated in the brain and heart and involved in the serotonin, dopamine, and glutamate neurotransmitter systems [<a href="#rid83">83,84</a>]. Small clinical trials suggest that treatment with inositol may be efficacious for panic disorder, agoraphobia, and OCD.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panic disorder</strong> – A clinical trial with a crossover design compared adjunctive treatment with inositol to placebo over four weeks in 21 patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of panic disorder with and without agoraphobia [<a href="#rid83">83</a>]. Patients receiving inositol experienced a greater reduction in panic attacks compared with placebo (from 10 to 3.7 versus 10 to 6.3 panic attacks) and a decrease in the severity of agoraphobia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obsessive-compulsive disorder </strong>– A clinical trial with a crossover design compared adjunctive inositol with placebo in 13 patients with OCD over six weeks [<a href="#rid85">85</a>]. Patients receiving inositol had lower scores on the Y-BOCS at the end of the period compared with controls.</p><p></p><p class="headingAnchor" id="H4894538"><span class="h3">Omega-3 (n-3) polyunsaturated fatty acids</span><span class="headingEndMark"> — </span>n-3 PUFA, which is found in fish oil, reduced anxiety in small clinical trials, but has not been studied for anxiety disorders.</p><p>Systematic reviews and meta-analysis have shown conflicting results in the treatment of anxiety symptoms. While one meta-analysis of 19 trials and over 2000 participants showed improvements in severity of anxiety symptoms with n-3 PUFAs, a larger meta-analysis of 31 trials including over 41,000 participants showed that n-3 PUFAs has little or no effect in preventing anxiety symptoms [<a href="#rid86">86,87</a>].</p><p>n-3 PUFA protects neurotransmission from glucocorticoids, which are released during the body’s stress response [<a href="#rid88">88</a>]. It is postulated that this protective effect, particularly on excitatory glutamatergic neurotransmitter systems, underlies a potential therapeutic benefit of n-3 PUFA on anxiety.</p><p class="headingAnchor" id="H109704281"><span class="h3">L-lysine and l-arginine</span><span class="headingEndMark"> — </span>The essential amino acids <a class="drug drug_general" data-topicid="10114" href="/d/drug information/10114.html" rel="external">L-lysine</a> (Lys) and L-arginine (Arg) have been shown to reduce anxiety and stress hormone reactions in individuals with high levels of anxiety [<a href="#rid89">89</a>]. A clinical trial of 107 healthy volunteers were randomly assigned to receive L-lysine and L-arginine or placebo daily [<a href="#rid90">90</a>]. After one week, participants assigned to the L-lysine/L-arginine group had lower levels of state and trait anxiety compared with the placebo group.</p><p class="headingAnchor" id="H109701903"><span class="h1">HOMEOPATHY</span><span class="headingEndMark"> — </span>Homeopathy, developed by a German clinician at the end of the 18<sup>th</sup> century, involves the administration of highly diluted doses of substances to treat illnesses [<a href="#rid91">91,92</a>]. Meta-analyses of 25 clinical trials of homeopathy for anxiety in samples drawn from diverse populations reported significant methodologic limitations and inconclusive results [<a href="#rid91">91,92</a>].</p><p>Homeopathy is described in greater detail separately. (See  <a class="medical medical_review" href="/d/html/14591.html" rel="external">"Homeopathy"</a>.)</p><p class="headingAnchor" id="H109704304"><span class="h1">AROMATHERAPY</span><span class="headingEndMark"> — </span>Aromatherapy, the practice of administering isolated volatile oils from plants via inhalation, massage, or internal use, has been utilized in the treatment of anxiety. A systematic review of 16 clinical trials examining the anxiolytic effects of aromatherapy for individuals with anxiety symptoms reported uncertain benefits due to methodologic limitations of the trials [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H109705272"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Clinical trials of herbal remedies and dietary supplements in anxiety symptoms and disorders have generally had small sample sizes and other methodologic limitations. Large-scale safety studies have been scarce and inconclusive. Interactions among different herbal remedies have received insufficient study. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1">We help our patients weigh the risks and benefits of using these products. We include remedies and supplements they are taking, particularly those known to interact with other drugs or cause adverse effects, as part of the medical history. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herbal remedies</strong> – None of the herbal remedies tested for anxiety disorders in clinical trials have been shown to be clearly effective or clearly ineffective. Trials suggest that kava and chamomile may reduce anxiety in people with generalized anxiety disorder (GAD). Findings from trials of valerian, passion flower, and St. John’s wort are either mixed or negative. (See <a class="local">'Herbal remedies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Serious adverse effects of herbal remedies tested in anxiety disorders include hepatotoxicity associated with kava and an anticoagulant effect with chamomile. We encourage patients not to underestimate the potential risks of herbal remedies. (See <a class="local">'Herbal remedies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary supplements </strong>– Small clinical trials of some substances have shown promising results, but at best provide weak supporting evidence; none can be recommended for use at present:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Zinc for obsessive-compulsive disorder (OCD) and panic disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Antioxidant vitamins for GAD</p><p class="bulletIndent2"><span class="glyph">•</span>Inositol for panic disorder, agoraphobia, and OCD</p><p class="bulletIndent2"><span class="glyph">•</span>n-3 PUFAs for anxiety</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10114" href="/d/drug information/10114.html" rel="external">L-lysine</a>/L-arginine for anxiety associated with cortisol deficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homeopathy</strong> – Homeopathy has not been shown to be efficacious for anxiety disorders or for anxiety symptoms in medically ill patients. Systematic reviews of the use of aromatherapy in the treatment of anxiety disorders have reported unclear benefits. (See <a class="local">'Homeopathy'</a> above and <a class="local">'Aromatherapy'</a> above and  <a class="medical medical_review" href="/d/html/14591.html" rel="external">"Homeopathy"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bystritsky A, Hovav S, Sherbourne C, et al. Use of complementary and alternative medicine in a large sample of anxiety patients. Psychosomatics 2012; 53:266.</a></li><li><a class="nounderline abstract_t">Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; :1.</a></li><li><a class="nounderline abstract_t">Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; :1.</a></li><li><a class="nounderline abstract_t">Konnopka A, Leichsenring F, Leibing E, König HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 2009; 114:14.</a></li><li><a class="nounderline abstract_t">Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001; 158:289.</a></li><li><a class="nounderline abstract_t">Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008; 25:72.</a></li><li><a class="nounderline abstract_t">Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry 1997; 58 Suppl 11:30.</a></li><li><a class="nounderline abstract_t">Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, Part 1: a review of preclinical studies. CNS Drugs 2013; 27:207.</a></li><li><a class="nounderline abstract_t">Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry 2011; 45:27.</a></li><li><a class="nounderline abstract_t">Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20:1182.</a></li><li><a class="nounderline abstract_t">Bhate H, Gerster G, Gracza E. Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie. Erfahrungsheilkunde 1989; 38:339.</a></li><li><a class="nounderline abstract_t">Boerner RJ, Sommer H, Berger W, et al. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 2003; 10 Suppl 4:38.</a></li><li><a class="nounderline abstract_t">Connor KM, Davidson JR. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int Clin Psychopharmacol 2002; 17:185.</a></li><li><a class="nounderline abstract_t">Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006; 21:249.</a></li><li><a class="nounderline abstract_t">Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Phytomedicine 2003; 10:631.</a></li><li><a class="nounderline abstract_t">Geier FP, Konstantinowicz T. Kava treatment in patients with anxiety. Phytother Res 2004; 18:297.</a></li><li><a class="nounderline abstract_t">Kinzler E, Krömer J, Lehmann E. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. Arzneimittelforschung 1991; 41:584.</a></li><li><a class="nounderline abstract_t">Lehmann E. Wirkung bei Kava - Kava bei akuter Angst. Synopsis 1998; 2:57.</a></li><li><a class="nounderline abstract_t">Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996; 3:113.</a></li><li><a class="nounderline abstract_t">Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord 2004; 78:101.</a></li><li><a class="nounderline abstract_t">Lindenberg D, Pitule-Schödel H. [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness]. Fortschr Med 1990; 108:49.</a></li><li><a class="nounderline abstract_t">Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl) 2001; 157:277.</a></li><li><a class="nounderline abstract_t">Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009; 205:399.</a></li><li><a class="nounderline abstract_t">Singh N, Ellis C, Sharp I, et al. A double-blind, placebo-controlled study of the effects of kava (kavatrol) on daily stress and anxiety in adults. Alternative therapies 1998; 4:97.</a></li><li><a class="nounderline abstract_t">Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30:1.</a></li><li><a class="nounderline abstract_t">Warnecke G. [Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490]. Fortschr Med 1991; 109:119.</a></li><li><a class="nounderline abstract_t">Warnecke G, Pfaender H, Gerster G, Gracza E. Efficacy of an extract of kavaroot in patients with climacteric syndrome. Zeitschrift fur Phytotherapie 1990; 11:81.</a></li><li><a class="nounderline abstract_t">Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005; 19:183.</a></li><li><a class="nounderline abstract_t">Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003; :CD003383.</a></li><li><a class="nounderline abstract_t">Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003; 18:451.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. MMWR Morb Mortal Wkly Rep 2002; 51:1065.</a></li><li><a class="nounderline abstract_t">Ernst E. Safety concerns about kava. Lancet 2002; 359:1865.</a></li><li><a class="nounderline abstract_t">Wooltorton E. Herbal kava: reports of liver toxicity. CMAJ 2002; 166:777.</a></li><li><a class="nounderline abstract_t">Campo JV, McNabb J, Perel JM, et al. Kava-induced fulminant hepatic failure. J Am Acad Child Adolesc Psychiatry 2002; 41:631.</a></li><li><a class="nounderline abstract_t">Gow PJ, Connelly NJ, Hill RL, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178:442.</a></li><li><a class="nounderline abstract_t">Stickel F, Baumüller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39:62.</a></li><li class="breakAll">Food and Drug Administration Consumer Advisory: Kava-Containing Dietary Supplements May be Associated With Severe Liver Injury, 2002.</li><li><a class="nounderline abstract_t">Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16:650.</a></li><li><a class="nounderline abstract_t">Movafegh A, Alizadeh R, Hajimohamadi F, et al. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg 2008; 106:1728.</a></li><li><a class="nounderline abstract_t">Srivastava JK, Pandey M, Gupta S. Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci 2009; 85:663.</a></li><li><a class="nounderline abstract_t">Cemek M, Kağa S, Simşek N, et al. Antihyperglycemic and antioxidative potential of Matricaria chamomilla L. in streptozotocin-induced diabetic rats. J Nat Med 2008; 62:284.</a></li><li><a class="nounderline abstract_t">Hernández-Ceruelos A, Madrigal-Bujaidar E, de la Cruz C. Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methyl methanesulfonate in mouse bone marrow. Toxicol Lett 2002; 135:103.</a></li><li><a class="nounderline abstract_t">Ogata-Ikeda I, Seo H, Kawanai T, et al. Cytotoxic action of bisabololoxide A of German chamomile on human leukemia K562 cells in combination with 5-fluorouracil. Phytomedicine 2011; 18:362.</a></li><li><a class="nounderline abstract_t">Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007; 30:233.</a></li><li><a class="nounderline abstract_t">Srivastava JK, Gupta S. Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J Agric Food Chem 2007; 55:9470.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol 2009; 29:378.</a></li><li><a class="nounderline abstract_t">Mao JJ, Xie SX, Keefe JR, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine 2016; 23:1735.</a></li><li><a class="nounderline abstract_t">Andres C, Chen WC, Ollert M, et al. Anaphylactic reaction to camomile tea. Allergol Int 2009; 58:135.</a></li><li class="breakAll">Newall CA, Anderson LA, Phillipson JD. Herbal medicines : a guide for health-care professionals, Pharmaceutical Press, London 1996.</li><li><a class="nounderline abstract_t">Mazidi M, Shemshian M, Mousavi SH, et al. A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. J Complement Integr Med 2016; 13:195.</a></li><li><a class="nounderline abstract_t">Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. J Affect Disord 2015; 174:51.</a></li><li><a class="nounderline abstract_t">Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician 2007; 76:549.</a></li><li><a class="nounderline abstract_t">Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005; 20:299.</a></li><li><a class="nounderline abstract_t">Kobak KA, Taylor LV, Warner G, Futterer R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005; 25:51.</a></li><li><a class="nounderline abstract_t">Mannel M, Kuhn U, Schmidt U, et al. St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial. J Psychiatr Res 2010; 44:760.</a></li><li><a class="nounderline abstract_t">Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002; 164:294.</a></li><li><a class="nounderline abstract_t">Wallace RB, Gryzlak BM, Zimmerman MB, Nisly NL. Application of FDA adverse event report data to the surveillance of dietary botanical supplements. Ann Pharmacother 2008; 42:653.</a></li><li><a class="nounderline abstract_t">Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl) 2001; 156:481.</a></li><li><a class="nounderline abstract_t">Leite JR, Seabra Mde L, Maluf E, et al. Pharmacology of lemongrass (Cymbopogon citratus Stapf). III. Assessment of eventual toxic, hypnotic and anxiolytic effects on humans. J Ethnopharmacol 1986; 17:75.</a></li><li><a class="nounderline abstract_t">Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med 2008; 14:175.</a></li><li><a class="nounderline abstract_t">Wolfson P, Hoffmann DL. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med 2003; 9:74.</a></li><li><a class="nounderline abstract_t">Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 2010; 17:94.</a></li><li><a class="nounderline abstract_t">Alijaniha F, Naseri M, Afsharypuor S, et al. Heart palpitation relief with Melissa officinalis leaf extract: double blind, randomized, placebo controlled trial of efficacy and safety. J Ethnopharmacol 2015; 164:378.</a></li><li><a class="nounderline abstract_t">Ghazizadeh J, Sadigh-Eteghad S, Marx W, et al. The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis. Phytother Res 2021; 35:6690.</a></li><li><a class="nounderline abstract_t">Sayyah M, Boostani H, Pakseresht S, Malaieri A. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1513.</a></li><li><a class="nounderline abstract_t">Sayyah M, Boostani H, Pakseresht S, Malayeri A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:362.</a></li><li><a class="nounderline abstract_t">Młyniec K, Davies CL, de Agüero Sánchez IG, et al. Essential elements in depression and anxiety. Part I. Pharmacol Rep 2014; 66:534.</a></li><li><a class="nounderline abstract_t">Shohag H, Ullah A, Qusar S, et al. Alterations of serum zinc, copper, manganese, iron, calcium, and magnesium concentrations and the complexity of interelement relations in patients with obsessive-compulsive disorder. Biol Trace Elem Res 2012; 148:275.</a></li><li><a class="nounderline abstract_t">Sayyah M, Olapour A, Saeedabad Ys, et al. Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial. Nutrition 2012; 28:892.</a></li><li><a class="nounderline abstract_t">Nahar Z, Azad MA, Rahman MA, et al. Comparative analysis of serum manganese, zinc, calcium, copper and magnesium level in panic disorder patients. Biol Trace Elem Res 2010; 133:284.</a></li><li><a class="nounderline abstract_t">Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses 2006; 67:362.</a></li><li><a class="nounderline abstract_t">Gautam M, Agrawal M, Gautam M, et al. Role of antioxidants in generalised anxiety disorder and depression. Indian J Psychiatry 2012; 54:244.</a></li><li><a class="nounderline abstract_t">Sánchez-Villegas A, Doreste J, Schlatter J, et al. Association between folate, vitamin B(6) and vitamin B(12) intake and depression in the SUN cohort study. J Hum Nutr Diet 2009; 22:122.</a></li><li><a class="nounderline abstract_t">Skarupski KA, Tangney C, Li H, et al. Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. Am J Clin Nutr 2010; 92:330.</a></li><li><a class="nounderline abstract_t">Herbison CE, Hickling S, Allen KL, et al. Low intake of B-vitamins is associated with poor adolescent mental health and behaviour. Prev Med 2012; 55:634.</a></li><li><a class="nounderline abstract_t">Türksoy N, Bilici R, Yalçıner A, et al. Vitamin B12, folate, and homocysteine levels in patients with obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2014; 10:1671.</a></li><li><a class="nounderline abstract_t">Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry 2013; 202:100.</a></li><li><a class="nounderline abstract_t">McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008; 22:982.</a></li><li><a class="nounderline abstract_t">Bossola M, Ciciarelli C, Di Stasio E, et al. Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. Gen Hosp Psychiatry 2010; 32:125.</a></li><li><a class="nounderline abstract_t">Dean AJ, Bellgrove MA, Hall T, et al. Effects of vitamin D supplementation on cognitive and emotional functioning in young adults--a randomised controlled trial. PLoS One 2011; 6:e25966.</a></li><li><a class="nounderline abstract_t">Slow S, Florkowski CM, Chambers ST, et al. Effect of monthly vitamin D3 supplementation in healthy adults on adverse effects of earthquakes: randomised controlled trial. BMJ 2014; 349:g7260.</a></li><li><a class="nounderline abstract_t">Camfield DA, Sarris J, Berk M. Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:887.</a></li><li><a class="nounderline abstract_t">Benjamin J, Agam G, Levine J, et al. Inositol treatment in psychiatry. Psychopharmacol Bull 1995; 31:167.</a></li><li><a class="nounderline abstract_t">Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014; 29:55.</a></li><li><a class="nounderline abstract_t">Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996; 153:1219.</a></li><li><a class="nounderline abstract_t">Su KP, Tseng PT, Lin PY, et al. Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis. JAMA Netw Open 2018; 1:e182327.</a></li><li><a class="nounderline abstract_t">Deane KHO, Jimoh OF, Biswas P, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. Br J Psychiatry 2021; 218:135.</a></li><li><a class="nounderline abstract_t">Hennebelle M, Champeil-Potokar G, Lavialle M, et al. Omega-3 polyunsaturated fatty acids and chronic stress-induced modulations of glutamatergic neurotransmission in the hippocampus. Nutr Rev 2014; 72:99.</a></li><li><a class="nounderline abstract_t">Jezova D, Makatsori A, Smriga M, et al. Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety. Nutr Neurosci 2005; 8:155.</a></li><li><a class="nounderline abstract_t">Smriga M, Ando T, Akutsu M, et al. Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res 2007; 28:85.</a></li><li><a class="nounderline abstract_t">Davidson JR, Crawford C, Ives JA, Jonas WB. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. J Clin Psychiatry 2011; 72:795.</a></li><li><a class="nounderline abstract_t">Pilkington K, Kirkwood G, Rampes H, et al. Homeopathy for anxiety and anxiety disorders: a systematic review of the research. Homeopathy 2006; 95:151.</a></li><li><a class="nounderline abstract_t">Lee YL, Wu Y, Tsang HW, et al. A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms. J Altern Complement Med 2011; 17:101.</a></li></ol></div><div id="topicVersionRevision">Topic 14624 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22304968" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Use of complementary and alternative medicine in a large sample of anxiety patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19361005" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Complementary and alternative medicine use among adults and children: United States, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188733" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complementary and alternative medicine use among adults: United States, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768222" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156813" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The use of complementary and alternative therapies to treat anxiety and depression in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146763" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Human and economic burden of generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9363046" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Placebo response in generalized anxiety: its effect on the outcome of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23436255" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Plant-based medicines for anxiety disorders, Part 1: a review of preclinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21073405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Kava: a comprehensive review of efficacy, safety, and psychopharmacology</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989142" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807341" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131602" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A placebo-controlled study of Kava kava in generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877894" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Kava in generalized anxiety disorder: three placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692723" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15162364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Kava treatment in patients with anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1930344" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Wirkung bei Kava - Kava bei akuter Angst</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23194958" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706720" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179082" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11605083" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430766" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A double-blind, placebo-controlled study of the effects of kava (kavatrol) on daily stress and anxiety in adults</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2029982" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of an extract of kavaroot in patients with climacteric syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934028" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535473" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Kava extract for treating anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950418" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systematic review: hepatotoxic events associated with herbal medicinal products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12500906" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044412" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety concerns about kava.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11944767" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Herbal kava: reports of liver toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049436" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Kava-induced fulminant hepatic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12720510" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fatal fulminant hepatic failure induced by a natural therapy containing kava.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821045" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hepatitis induced by Kava (Piper methysticum rhizoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821045" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hepatitis induced by Kava (Piper methysticum rhizoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410546" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499602" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19788894" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404309" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antihyperglycemic and antioxidative potential of Matricaria chamomilla L. in streptozotocin-induced diabetic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243869" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methyl methanesulfonate in mouse bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20863677" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cytotoxic action of bisabololoxide A of German chamomile on human leukemia K562 cells in combination with 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143534" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Apigenin and cancer chemoprevention: progress, potential and promise (review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17939735" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593179" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27912875" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050375" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anaphylactic reaction to camomile tea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050375" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anaphylactic reaction to camomile tea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27101556" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25484177" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17853630" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Herbal and dietary supplements for treatment of anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192837" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643100" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181361" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12424553" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397972" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Application of FDA adverse event report data to the surveillance of dietary botanical supplements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11498727" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2429120" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pharmacology of lemongrass (Cymbopogon citratus Stapf). III. Assessment of eventual toxic, hypnotic and anxiolytic effects on humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18307390" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12652886" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19962288" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25680840" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Heart palpitation relief with Melissa officinalis leaf extract: double blind, randomized, placebo controlled trial of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34449930" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737592" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20035818" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24948052" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Essential elements in depression and anxiety. Part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22383079" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alterations of serum zinc, copper, manganese, iron, calcium, and magnesium concentrations and the complexity of interelement relations in patients with obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22465904" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19582379" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparative analysis of serum manganese, zinc, calcium, copper and magnesium level in panic disorder patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542786" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rapid recovery from major depression using magnesium treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23226848" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Role of antioxidants in generalised anxiety disorder and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19175490" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Association between folate, vitamin B(6) and vitamin B(12) intake and depression in the SUN cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519557" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23010437" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Low intake of B-vitamins is associated with poor adolescent mental health and behaviour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25228807" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Vitamin B12, folate, and homocysteine levels in patients with obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23377209" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Vitamin D deficiency and depression in adults: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056830" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20302985" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Correlates of symptoms of depression and anxiety in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22073146" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effects of vitamin D supplementation on cognitive and emotional functioning in young adults--a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516139" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of monthly vitamin D3 supplementation in healthy adults on adverse effects of earthquakes: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352883" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675981" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Inositol treatment in psychiatry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424706" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A meta-analysis of inositol for depression and anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780431" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Inositol treatment of obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646157" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31647041" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24417620" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Omega-3 polyunsaturated fatty acids and chronic stress-induced modulations of glutamatergic neurotransmission in the hippocampus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16117182" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17510493" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21733480" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815519" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Homeopathy for anxiety and anxiety disorders: a systematic review of the research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21309711" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
